NASDAQ:HSKA - Heska Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $96.29 -1.10 (-1.13 %) (As of 01/23/2019 04:00 PM ET)Previous Close$97.39Today's Range$94.28 - $97.5852-Week Range$56.59 - $114.50Volume36,951 shsAverage Volume43,757 shsMarket Capitalization$730.74 millionP/E Ratio46.52Dividend YieldN/ABeta0.88 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging. The company sells its products to veterinarians through a field organization and third-party distributors; and trade shows, print advertising, and other distribution relationships. Heska Corporation has product development partnership and licensing agreement with MBio Diagnostics, Inc. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado. Receive HSKA News and Ratings via Email Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSKA Previous Symbol CUSIPN/A Webwww.heska.com Phone970-493-7272Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick Ratio1.26Price-To-Earnings Trailing P/E Ratio46.52 Forward P/E Ratio55.34 P/E GrowthN/A Sales & Book Value Annual Sales$129.34 million Price / Sales5.65 Cash Flow$2.8271 per share Price / Cash Flow34.06 Book Value$13.87 per share Price / Book6.94Profitability EPS (Most Recent Fiscal Year)$2.07 Net Income$9.95 million Net Margins1.01% Return on Equity11.48% Return on Assets8.83%Miscellaneous Employees345 Outstanding Shares7,589,000Market Cap$730.74 million OptionableNot Optionable Heska (NASDAQ:HSKA) Frequently Asked Questions What is Heska's stock symbol? Heska trades on the NASDAQ under the ticker symbol "HSKA." How were Heska's earnings last quarter? Heska Corp (NASDAQ:HSKA) issued its quarterly earnings results on Tuesday, November, 6th. The medical research company reported $0.46 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.35 by $0.11. The medical research company had revenue of $30.96 million for the quarter, compared to analysts' expectations of $31.14 million. Heska had a net margin of 1.01% and a return on equity of 11.48%. View Heska's Earnings History. When is Heska's next earnings date? Heska is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Heska. What price target have analysts set for HSKA? 4 analysts have issued 12-month target prices for Heska's stock. Their forecasts range from $93.00 to $123.00. On average, they anticipate Heska's share price to reach $107.50 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for Heska. What is the consensus analysts' recommendation for Heska? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heska. Has Heska been receiving favorable news coverage? News headlines about HSKA stock have trended somewhat positive on Wednesday, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Heska earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the next few days. Who are some of Heska's key competitors? Some companies that are related to Heska include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO) and Iovance Biotherapeutics (IOVA). Who are Heska's key executives? Heska's management team includes the folowing people: Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)Mr. Jason A. Napolitano, COO, Chief Strategist & Sec. (Age 51)Ms. Catherine Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)Mr. Steven M. Eyl, Exec. VP of Global Sales & Marketing (Age 53)Mr. Jon Aagaard, Director of Investor Relations Who are Heska's major shareholders? Heska's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (4.67%), Summit Creek Advisors LLC (1.06%), Curbstone Financial Management Corp (0.07%), Louisiana State Employees Retirement System (0.03%) and Bank of Montreal Can (0.02%). Company insiders that own Heska stock include Bonnie J Trowbridge, Carol Wrenn, G Irwin Gordon, Jason A Napolitano, John Mcmahon, Kevin S Wilson, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott, Sharon J Larson, Steve Asakowicz and Steven M Eyl. View Institutional Ownership Trends for Heska. Which institutional investors are selling Heska stock? HSKA stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Louisiana State Employees Retirement System and Curbstone Financial Management Corp. Company insiders that have sold Heska company stock in the last year include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Nancy Wisnewski, Rod Lippincott, Steve Asakowicz and Steven M Eyl. View Insider Buying and Selling for Heska. Which institutional investors are buying Heska stock? HSKA stock was purchased by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC and Bank of Montreal Can. View Insider Buying and Selling for Heska. How do I buy shares of Heska? Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Heska's stock price today? One share of HSKA stock can currently be purchased for approximately $96.29. How big of a company is Heska? Heska has a market capitalization of $730.74 million and generates $129.34 million in revenue each year. The medical research company earns $9.95 million in net income (profit) each year or $2.07 on an earnings per share basis. Heska employs 345 workers across the globe. What is Heska's official website? The official website for Heska is http://www.heska.com. How can I contact Heska? Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected] MarketBeat Community Rating for Heska (NASDAQ HSKA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 256 (Vote Outperform)Underperform Votes: 270 (Vote Underperform)Total Votes: 526MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?